Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
278
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
stocks
This ASX stock’s bubble has well and truly burst
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,222.30 | 6.20 | -0.07% |
| CAC 40 | 7,709.81 | 133.23 | -1.70% |
| DAX 40 | 24,152.87 | 120.25 | -0.50% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,265.80 | 55.60 | -0.60% |
| HKSE | 25,521.73 | 3.19 | -0.01% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,529.95 | 135.55 | 0.32% |
| NZX 50 Index | 12,919.78 | 38.20 | -0.29% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,953.60 | 7.60 | -0.08% |
| SSE Composite Index | 3,865.16 | 3.22 | -0.08% |